NDAINJECTIONINJECTABLEPriority Review
Approved
Sep 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARAMINE (metaraminol bitartrate) is an injectable sympathomimetic amine used as a vasopressor to treat hypotension in acute care settings. It works by stimulating alpha and beta-adrenergic receptors to increase blood pressure and cardiac output. The drug is administered intravenously or intramuscularly in emergency and perioperative scenarios.
LOE Approaching
Limited commercial team expansion expected; product lifecycle approaching loss of exclusivity with minimal market growth opportunity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ARAMINE offers limited long-term career growth due to its LOE-approaching status and lack of active pipeline development. Opportunities are primarily in maintenance sales, cost management, and potential generic transition planning rather than expansion or innovation.
Brand ManagerSales Representative
Worked on ARAMINE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.